Ever wondered what happens when a hoard of journalism students meet leading life science industry experts? Well… we have documented it all for you here at the BIO-Europe live blog www.bio-live.de

Giving the next generation of science journalists an insight into the fascinating, yet intricately complex, life sciences industry isn’t always an easy task but nonetheless, a rewarding experience for both sides. Together with their partners EBD Group, Labiotech.eu and BIO Clustermanagement NRW GmbH, MC Services took on the challenge by introducing the “Bio-Live”-ProjectFirst introduced at the 2016 BIO-Europe conference, interested students from local journalism schools and universities, f.e. the Deutsche Journalistenschule, TU Dortmund and the Kölner Journalistenschule, were invited to conduct interviews with participants and report on their impressions of the event as well as highlights from panels, company presentations and discussions under the guidance of our in-house journalism and bio science experts.

The aim of this initiative is to provide a vivid picture of the event for interested people in and outside the conference as well as to get young journalists enthusiastic about the complex field of biotechnology. And, the outcome was surprising: well written and thought out articles, mood pictures, interviews and coverage of panel discussions with fresh insights and perspectives!  Find out more at: www.bio-live.de.[image_slider_no_space on_click=”use_custom_links” custom_links=”http://www.bio-live.de/curing-cancer-with-cell-and-gene-therapy/, http://www.bio-live.de/was-es-braucht-um-big-pharma-als-kooperationspartner-zu-gewinnen/, http://www.bio-live.de/man-braucht-ein-gewisses-fingerspitzengefuhl-fur-das-jeweilige-unternehmen/, http://www.bio-live.de/you-dont-reach-the-top-of-mount-everest-in-one-day/” custom_links_target=”_blank” height=”600″ navigation_style=”light” images=”3562,3563,3560,3566″]

Every year on February 4th, WORLD CANCER DAY aims to unite the world’s population in the fight against cancer by raising awareness for cancer and encouraging its prevention, detection, and treatment by pressing governments and individuals across the world to take action.

Founded by the Union for International Cancer Control (UICC) to support the goals of the World Cancer Declaration, written in 2008, the primary objective of World Cancer Day is to significantly reduce illness and death caused by cancer by 2020. However, cancer remains the second leading cause of death worldwide; over eight million people die from cancer annually and death rates are still on the rise. This certainly make the 2020 objective no small feat.

According to the World Health Organization (WHO), the number of cancer related deaths will increase annually to 13 million by 2030. Nevertheless, hope remains – European companies are successfully expanding the range of drugs and therapies to treat various cancer indications and are pushing the boundaries of science by developing individualized and targeted approaches to cancer treatments.On a positive note, never have so many new drugs and therapies been in development to treat cancer. Internationally, the first approval of a cancer gene therapy generated great excitement in August 2017, when Swiss-based pharma Novartis received FDA approval of Kymriah®, a CAR-T cell therapy to treat an aggressive form of leukemia.

Currently in Europe, approximately 400 companies are developing innovative approaches to fight cancer, andmany of our clients are actively involved in oncological indications. We introduced the World Cancer Day Blog in 2017 to provide an information platform for innovative  treatment options in development and emerging scientific approaches – giving great hope that in the future many types of cancer will at least have successful treatment options and eventually be curable. #WorldCancerDay #WeCanICan.

Find out more about how our clients support the fight against cancer: http://world-cancer-day.info/

Find out more about the World Cancer Day: http://www.worldcancerday.org/[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”2544,2545,2546,2547,2548,2549,2550,2551,2552″]

Two of our own, Dr Cora Kaiser, Consultant, and Shaun Brown, Executive Director, share their insights into the rapidly developing cancer therapies and how a tumor can be controlled by its own microenvironment: https://www.goingpublic.de/wp-content/uploads/sites/2/_EPAPER_/epaper-Life-Sciences-3-2017/#28

About the authors:

Dr. Cora Kaiser – Consultant at MC Services

Cora has specialized in Corporate Communications and PR/IR since 2012. She combines this expertise with over five years of international experience in biomedical research. She is a trained biotechnologist and holds a PhD in Neuroimmunology from the Max Planck Institute.

Shaun Brown – Executive Director at MC Services

Shaun provides 20 years of experience writing on and advising companies in the Life Sciences space. He focuses on Public and Investor Relations, advising on all aspects of communications. Before this, he spent over eight years as a reporter, news editor and senior writer with BioCentury.